Synthesis and evaluation of potential tumor localizing radiopharmaceuticals: Technetium‐99m iminodiacetic acid derivatives of sulfanilamides

Abstract

summaryTo exploit the tissue affinity of compounds for radiopharmaceutical purposes, attachment of chelating groups is usually necessary to facilitate technetium-99m binding and transport.The chelating group, iminodiacetic acid, previously used to modify lidocaine for hepatobiliary radiopharmaceuticals, was attached to several antibiotic sulfanilamides known to concentrate in certain transplanted animal tumors.These iminodiacetic acid derivatives were labelled with technetium-9% by the stannous chloride reduction method.Biodistribution of the ' % T c labelled compounds in tumor bearing rats revealed no specific concentration in the tumors and localization mainly in the excretory organs.The results indicate that, as in the case of lidocaine, conversion of the sulfanilamides into imindiacetic acid derivatives and chelation with technetium leads to an altered biodistribution and loss of biological specificity.

Synthesis of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) and derivatives

“…The first approach involves conversion of N,N1-di(2-hydroxybenzy1)ethylenediamine to the diamide (HBED-DA) via reaction with formaldehyde and HCN followed by hydrolysis. Because of the difficulty of hydrolyzing HBEDDA, 2, to HBED, 1, it was decided to investigate the promotion of lates may also be useful as radiopharmaceuticals for tumor H2NOC7 ,-, r C O N H 2 imaging purposes (4)(5)(6)(7).…”